What is HC Wainwright’s Estimate for TRVI FY2030 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – HC Wainwright cut their FY2030 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.65 per share for the year, down from their previous estimate of $0.70. HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.48) per share.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11).

Several other analysts have also recently commented on TRVI. Morgan Stanley reiterated an “overweight” rating and set a $23.00 price target on shares of Trevi Therapeutics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Friday, July 17th. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a report on Friday, April 17th. BMO Capital Markets initiated coverage on shares of Trevi Therapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $36.00 target price for the company. Finally, Wall Street Zen lowered shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.75.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $17.80 on Wednesday. The company has a market cap of $2.54 billion, a PE ratio of -52.35 and a beta of 1.03. The stock’s 50 day simple moving average is $17.13 and its 200-day simple moving average is $14.13. Trevi Therapeutics has a 1-year low of $6.93 and a 1-year high of $20.22.

Hedge Funds Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. KBC Group NV acquired a new position in Trevi Therapeutics in the first quarter valued at approximately $29,000. Hilton Head Capital Partners LLC acquired a new stake in Trevi Therapeutics during the fourth quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in Trevi Therapeutics during the fourth quarter worth $50,000. Russell Investments Group Ltd. raised its position in Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Trevi Therapeutics by 32.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares during the period. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.